Trial Profile
A Study to Evaluate the Long Term Efficacy and Safety of Natalizumab in Patients with Multiple Sclerosis (MS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms TYSABRI 24 PLUS
- 10 Dec 2015 New trial record